Anuh Pharma
NSE: ANUHPHR · ISIN INE489G01022 · Healthcare
₹83.38+0.59 (+0.71%)
Monday 9 November, 12:49 IST. Delayed. Source: Yahoo Finance.
Price chart
₹83.38 +0.59 (+0.71%) today
The day
- Previous close
- ₹82.79
- Open
- ₹83.90
- Day high
- ₹83.90
- Day low
- ₹82.21
Listed on NSE since 20 December 2024.
Key numbers
- Market value
- ₹829.75 Cr
- P/E (trailing)
- 18.77
- EPS (trailing)
- ₹4.41
- Price to book
- 2.30
- Dividend yield
- 1.84%
- Return on equity
- 13.9%
- Debt to equity
- 0.05
- Profit margin
- 6.1%
- Volume today
- 22,357
- Average volume
- 1.61 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹527.49 Cr | ₹36.18 Cr |
| FY24 | ₹647.00 Cr | ₹60.06 Cr |
| FY25 | ₹661.51 Cr | ₹47.35 Cr |
| FY26 | ₹771.66 Cr | ₹41.05 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported. EPS before FY26 is not shown: the share count changed (a bonus, split or merger), so earlier figures would not compare.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹185 Cr | ₹11 Cr | +47.3% |
| Q1 FY27Apr–Jun 2026 | ₹194 Cr | ₹11 Cr | +37.6% |
| Q4 FY26Jan–Mar 2026Audited | ₹202 Cr | ₹12 Cr | −6.2% |
| Q3 FY26Oct–Dec 2025 | ₹197 Cr | ₹13 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹186 Cr | ₹8 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹186 Cr | ₹8 Cr | – |
Source: Anuh Pharma’s results filed with NSE, standalone (the company alone). Net profit is the share of Anuh Pharma’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss. EPS before Q2 FY26 is not shown: the share count changed (a bonus, split or merger), so it would not compare.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹45 Cr | ₹48 Cr |
| Investments | ₹113 Cr | ₹84 Cr |
| Inventories | ₹172 Cr | ₹148 Cr |
| Owed by customers | ₹190 Cr | ₹239 Cr |
| Cash and equivalents | ₹9 Cr | ₹8 Cr |
| Total assets | ₹554 Cr | ₹557 Cr |
| Borrowings | ₹19 Cr | ₹0 |
| Total liabilities | ₹194 Cr | ₹205 Cr |
| Shareholders’ equity | ₹360 Cr | ₹352 Cr |
Source: Anuh Pharma’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.
About Anuh Pharma
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-hypertension, expectorant, anti-diabetics, anti-bacterial, anti-gout, anti asthmatics, quinolones, anti biotic, anti platelet, anti-histamines, and intermediates; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, and anti-mitotic. The company also develops products, such as anticoagulant, antagonist, anti convulsants, anty-ulcerative, anty-ulcerative, anticholinergics, anti-anemic, antidepressant, and mucolytic agents. It also exports its products. Anuh Pharma Limited was incorporated in 1960 and is headquartered in Mumbai, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Mumbai
- Employees
- 323
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Anuh Pharma in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 1.50 Per Share
Dividend · ex-date 5 August 2026
- Dividend - Rs 1.50 Per Share
Dividend · ex-date 14 August 2025 · record date 15 August 2025
- Bonus 1:1
Bonu · ex-date 15 July 2025
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.